Citation: | Wenchao Ma, Di Zhu, Tong Yu, Junwen Xue, Xiang Sun, Guofang Zhang, Yumeng Hou, Jinrui Li, Yingzhun Chen, Hongli Shan, Haihai Liang. Apelin aggravates the migration and invasion of nonsmall cell lung cancer cells via YAP1[J]. Frigid Zone Medicine, 2022, 2(1): 53-64. doi: 10.2478/fzm-2022-0007 |
[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2020; 70(4): 313.
|
[2] |
Zhang M, Yang W, Wang P, et al. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nat Commun, 2020; 11(1): 6119. doi: 10.1038/s41467-020-19973-6
|
[3] |
Kwak E L, Bang Y J, Camidge D R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010; 363(18): 1693-1703. doi: 10.1056/NEJMoa1006448
|
[4] |
Hamanaka N, Nakanishi Y, Mizuno T, et al. YES1 is a targetable oncogene in cancers harboring YES1 gene amplification. Cancer Res, 2019; 79(22): 5734-5745. doi: 10.1158/0008-5472.CAN-18-3376
|
[5] |
Sorli S C, Le Gonidec S, Knibiehler B, et al. Apelin is a potent activator of tumour neoangiogenesis. Oncogene, 2007; 26(55): 7692-7699. doi: 10.1038/sj.onc.1210573
|
[6] |
O'Carroll A M, Lolait S J, Harris L E, et al. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol, 2013; 219(1): R13-35. doi: 10.1530/JOE-13-0227
|
[7] |
Li Z, He Q, Wu C, et al. Apelin shorten QT interval by inhibiting Kir2.1/IK1 via a PI3K way in acute myocardial infarction. Biochem Bioph Res Co, 2019; 517(2): 272-277. doi: 10.1016/j.bbrc.2019.07.041
|
[8] |
Berta J, Kenessey I, Dobos J, et al. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol, 2010; 5(8): 1120-1129. doi: 10.1097/JTO.0b013e3181e2c1ff
|
[9] |
Yang Y, Lv S Y, Ye W, et al. Apelin/APJ system and cancer. Clin Chim Acta, 2016; 457: 112-116. doi: 10.1016/j.cca.2016.04.001
|
[10] |
Yu F X, Zhao B, Guan K L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell, 2015; 163(4): 811-828. doi: 10.1016/j.cell.2015.10.044
|
[11] |
Zhang Z, Du J, Wang S, et al. OTUB2 promotes cancer metastasis via hippo-independent activation of YAP and TAZ. Mol Cell, 2019; 73(1): 7-21 e7. doi: 10.1016/j.molcel.2018.10.030
|
[12] |
Zanconato F, Piccolo S. Eradicating tumor drug resistance at its YAP-biomechanical roots. EMBO J, 2016; 35(5): 459-461. doi: 10.15252/embj.201593584
|
[13] |
Yu M, Chen Y, Li X, et al. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD. Cell Death Dis, 2018; 9(5): 464. doi: 10.1038/s41419-018-0515-z
|
[14] |
Liang H, Yu T, Han Y, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer, 2018; 17(1): 119. doi: 10.1186/s12943-018-0870-5
|
[15] |
Wu M, Duan Q, Liu X, et al. MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2. Biomed Pharmacother, 2020; 122: 109696. doi: 10.1016/j.biopha.2019.109696
|
[16] |
Li X, Yu T, Shan H, et al. lncRNA PFAL promotes lung fibrosis through CTGF by competitively binding miR-18a. FASEB J, 2018; 32(10): 5285-5297. doi: 10.1096/fj.201800055R
|
[17] |
Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Bioph Res Co, 1998; 251(2): 471-476. doi: 10.1006/bbrc.1998.9489
|
[18] |
Cano Martinez L J, Coral Vazquez R M, Mendez J P, et al. Serum concentrations of apelin-17 isoform vary in accordance to blood pressure categories in individuals with obesity class 3. Clin Exp Hypertens, 2019; 41(2): 168-173. doi: 10.1080/10641963.2018.1462374
|
[19] |
Yan J, Wang A, Cao J, et al. Apelin/APJ system: an emerging therapeutic target for respiratory diseases. Cell Mol Life Sci, 2020; 77(15): 2919-2930. doi: 10.1007/s00018-020-03461-7
|
[20] |
Wu L, Chen L, Li L. Apelin/APJ system: a novel promising therapy target for pathological angiogenesis. Clin Chim Acta, 2017; 466: 78-84. doi: 10.1016/j.cca.2016.12.023
|
[21] |
Xie H, Yuan L Q, Luo X H, et al. Apelin suppresses apoptosis of human OBs. Apoptosis, 2007; 12(1): 247-254. doi: 10.1007/s10495-006-0489-7
|
[22] |
Yu X H, Tang Z B, Liu L J, et al. Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta, 2014; 428: 1-8. doi: 10.1016/j.cca.2013.09.001
|
[23] |
Podgorska M, Pietraszek-Gremplewicz K, Nowak D. Apelin effects migration and invasion abilities of colon cancer cells. Cells, 2018; 7(8): 113. doi: 10.3390/cells7080113
|
[24] |
Lv D, Li L, Lu Q, et al. PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13. Clin Exp Pharmacol Physiol, 2016; 43(5): 569-579. doi: 10.1111/1440-1681.12563
|
[25] |
Masoumi J, Jafarzadeh A, Khorramdelazad H, et al. Role of Apelin/APJ axis in cancer development and progression. Adv Med Sci, 2020; 65(1): 202-213. doi: 10.1016/j.advms.2020.02.002
|
[26] |
Plouffe S W, Hong A W, Guan K L. Disease implications of the Hippo/YAP pathway. Trends Mol Med, 2015; 21(4): 212-222. doi: 10.1016/j.molmed.2015.01.003
|
[27] |
Cao J J, Zhao X M, Wang D L, et al. YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis. Oncol Rep, 2014; 32(4): 1594-1600. doi: 10.3892/or.2014.3349
|
[28] |
Malik S A, Khan M S, Dar M, et al. Molecular alterations and expression dynamics of LATS1 and LATS2 genes in non-small-cell lung carcinoma. Pathol Oncol Res, 2018; 24(2): 207-214. doi: 10.1007/s12253-017-0225-3
|
[29] |
Pan D. The hippo signaling pathway in development and cancer. Dev Cell, 2010; 19(4): 491-505. doi: 10.1016/j.devcel.2010.09.011
|
[30] |
Mao X Y, Li Q Q, Gao Y F, et al. Gap junction as an intercellular glue: Emerging roles in cancer EMT and metastasis. Cancer Lett, 2016; 381(1): 133-137. doi: 10.1016/j.canlet.2016.07.037
|
[31] |
Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell, 2007; 130(6): 1120-1133. doi: 10.1016/j.cell.2007.07.019
|
[32] |
Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell, 2011; 147(4): 759-772.
|
[33] |
Gao J, He L, Zhou L, et al. Mechanical force regulation of YAP by F-actin and GPCR revealed by super-resolution imaging. Nanoscale, 2020; 12(4): 2703-2714.
|
[34] |
Dorsam R T, Gutkind J S. G-protein-coupled receptors and cancer. Nat Rev Cancer, 2007; 7(2): 79-94.
|
[35] |
Yu F X, Zhang Y, Park H W, et al. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Gene Dev, 2013; 27(11): 1223-1232.
|
[36] |
Yu F X, Mo J S, Guan K L. Upstream regulators of the Hippo pathway. Cell Cycle, 2012; 11(22): 4097-4098.
|
[37] |
Luo J, Yu F X. GPCR-Hippo Signaling in Cancer. Cells, 2019; 8(5): 426.
|